2015 American Transplant Congress
Virus Induced CD28 Down-Regulation as a Potential Driver of Costimulation Blockade Resistant Rejection
1Surgery, Emory University, Atlanta, GA; 2Surgery, Duke University, Durham, NC.
Belatacept, a B7-specific fusion protein, blocks CD28-B7 costimulation and prevents kidney allograft rejection. However, it is ineffective in a sizable minority of patients. Although T…2015 American Transplant Congress
Human CMV-Specific CD8 T Cells Exhibit Distinct Phenotypes and Distribution Patterns in Tissues and Circulation
IntroductionCMV persists and is controlled by T cells in multiple tissues; however, study of CMV responses has largely been limited to blood containing only 2-3%…2015 American Transplant Congress
Analysis of In-Vitro Effects of Immunosuppression on NK Cell Subsets in the Presence of Cytomegalovirus
Background: NK cells may play an important role in the control of CMV replication post-transplant. NK cells can be divided into subsets based on surface…2015 American Transplant Congress
CMV IgG Provides Similar Anti-CMV Efficacy as Valganciclovir in High-Risk Organ Transplant Recipients, With Reduced Costs
Abdominal organ transplants at high risk for CMV infection (D+/R-) remain a difficult cohort to prevent late CMV infection despite prolonged valganciclovir (VGC) administration. Administration…2015 American Transplant Congress
Incidence of CMV Viremia in Obese and Morbidly Obese Kidney Transplants Under a Low Dose Valganciclovir Prophylaxis Protocol
1Pharmacy Practice, Univ of IL-Chicago, Chicago, IL; 2Surgery, Univ of IL-Chicago, Chicago, IL.
Background: The rate of Cytomegalovirus infections in kidney transplant recipients drastically diminished with the advent of oral ganciclovir and subsequently valganciclovir. However it continues to…2015 American Transplant Congress
Favorable Long-Term Outcome of Late-Onset CMV Disease in D+R- Kidney Transplant Recipients Treated With Universal Prophylaxis
Based on last international guidelines, both universal prophylaxis and preemptive strategies are viable approaches for the prevention of cytomegalovirus (CMV) disease after organ transplantation. Universal…2015 American Transplant Congress
Diabetic Kidney Transplant Recipients: Impaired Infection Control and Alloreactivity
New onset diabetes after transplant (NODAT) has been associated with an increased risk of infection and sepsis. Previous studies, however, failed to identify differences in…2015 American Transplant Congress
African American Race Is an Independent Risk Factor for Cytomegalovirus Infection in Renal Transplant Recipients on Low-Dose Valganciclovir Prophylaxis
Houston Methodist Hospital, Houston, TX.
Safe and effective use of low-dose (450 mg/day) valganciclovir (VGC) for cytomegalovirus (CMV) prophylaxis in renal transplant recipients (RTRs) has been reported. However, it is…2015 American Transplant Congress
Recipient Immunity to Murine Cytomegalovirus Influences Natural Killer Cell Responses in Infected Renal Allografts
BACKGROUND: Human cytomegalovirus (CMV) is associated epidemiologically with renal allograft loss, but the impact of recipient CMV immunity upon graft survival is unclear. Natural killer…2015 American Transplant Congress
Recurrent Cytomegalovirus Infection After Solid Organ Transplant
University Health Network, Toronto, Canada.
Background:Cytomegalovirus is a common opportunistic infection after transplant. Relapse may occur after treatment of the initial episode of viremia or disease and secondary prophylaxis is…
American Transplant Congress abstracts